Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
1 result
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
Int J Cancer. 2021 Sep 15;149(6):1313-1321. doi: 10.1002/ijc.33695. Epub 2021 May 27.
Int J Cancer. 2021.
PMID: 34019700
Free article.
Clinical Trial.
Cite
Cite